<DOC>
	<DOCNO>NCT01017536</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , placebo-controlled trial conduct 1 site South Africa . A total 26 subject randomize 1:1 receive 2 dos either AERAS-402 3 x 10^10 vp ( N=13 ) placebo ( N=13 ) Study Days 0 28 . Dose-escalation second group 40 subject plan , although safety concern identify , sponsor decide continue study .</brief_summary>
	<brief_title>Safety Immunogenicity AERAS-402 HIV-infected , Bacillus Calmette-Guerin ( BCG ) -Vaccinated Adults</brief_title>
	<detailed_description>Further study detail provide Aeras .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Age 21 year 45 year ( i.e. , subject yet reach his/her 46th birthday day randomization ) . 2 . Had complete write informed consent process prior undergo screen evaluation . 3 . Had BCG vaccination least 5 year previously , document medical history presence scar . 4 . Females : Ability avoid pregnancy least 6 month receive last study vaccination : Women physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) must avoid pregnancy 28 day prior administration study vaccine must agree avoid pregnancy least 6 month receive last study vaccination . Acceptable method avoid pregnancy include sterile sexual partner , sexual abstinence ( engage sexual intercourse ) , use combination least two form acceptable contraception : hormonal contraceptive ( oral , injection , transdermal patch , implant ) , vaginal ring , intrauterine device ( IUD ) , use condom diaphragm ; use condom diaphragm combine spermicide . 5 . Was able carry activity daily live independently . 6 . Had Body Mass Index ( BMI ) least 19 ( wt./ht.2 ) nomogram . 7 . Had ability complete followup period require protocol . 8 . Was able willing commit avoid elective surgery least 6 month receive last study vaccination . 9 . Was able willing stay contact study site duration study . 10 . Had commit simultaneous enrollment Aeras Vaccine Development Registry Protocol . 11 . Had laboratory evidence human immunodeficiency virus ( HIV ) infection , define positive HIV1 ELISA test plus positive confirmatory test ( e.g. , second HIV1 ELISA , PCR , rapid ELISA ) . 12 . Had four ( 4 ) ( Group 1 ) three ( 3 ) ( Group 2 ) * CD4+ lymphocyte count test , perform least four day apart within 42day screening period , least three ( Group 1 ) two ( Group 2 ) CD4+ lymphocyte count result great 350 cell / mm3 . 13 . Not currently receive antiretroviral drug . 14 . Committed participate clinical trial first 12 month participation study . 1 . Acute illness . 2 . Fever ≥37.5°C . 3 . Significant symptomatic infection . 4 . Used immunosuppressive medication within 42 day prior randomization ( inhaled topical corticosteroid permit ) . 5 . Received immunoglobulin blood product within 42 day prior randomization . 6 . Received investigational drug therapy vaccine within 182 day prior randomization . 7 . History receive adenovirusvectorbased vaccine . 8 . Medical history may compromise evaluation safety subject study ( e.g. , diabetes , seizure disorder , sickle cell disease ) . 9 . Pregnant breastfeed female , intention become pregnant study within 6 month receive last study vaccination . 10 . Liver function test &gt; Grade 2 per toxicity table . 11 . Currently receive treatment TB , evidence active TB disease base history , physical examination , chest Xray , laboratory evaluation ( INH prophylaxis permit ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Vaccine</keyword>
</DOC>